Comparative Pharmacology
Head-to-head clinical analysis: CIPRO HC versus MUPIROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO HC versus MUPIROCIN.
CIPRO HC vs MUPIROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
None Documented
None Documented
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Category C
Category A/B
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic